业绩经营情况 经济观察网宝莱特（300246）近期主要热点集中于2025年业绩预亏公告的发布及股价的震荡走势。 股票近期走势 近期宝莱特股价震荡明显，近5个交易日累计下跌0.74%，区间振幅达15.66%。资金流向方面，2月12日 主力资金净流出303.71万元，占总成交额2.14%，但游资资金净流入505.01万元。成交活跃度较高，2月 10日单日换手率超9%，反映市场分歧加剧。技术面显示，股价当前处于布林带中轨附近，20日压力位 14.63元，支撑位12.35元，MACD指标偏弱。 以上内容基于公开资料整理，不构成投资建议。 宝莱特于2026年2月11日发布业绩预亏公告，预计2025年归母净利润亏损6000万元至8000万元，较上年 同期亏损幅度有所收窄。亏损主因包括市场竞争导致产品价格下降、原材料成本上涨拉低毛利率，以及 美元汇兑损失和可转债摊销费用影响。公司表示，通过控费增效措施，费用同比降低，但资产减值准备 计提对净利润产生一定压力。 ...

证券代码：300246 证券简称：宝莱特 公告编号：2026-005 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、证券代码：300246，证券简称：宝莱特 2、债券代码：123065，债券简称：宝莱转债 3、转股价格：23.97 元/股 4、转股期限：2021 年 3 月 11 日至 2026 年 9 月 3 日 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）规定：在本次发行的可转 换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格的90%时，公司董事会有权提出转股价格向下修正 方案并提交公司股东会表决。 2026年1月30日至2026年2月12日，公司股票已有10个交易日的收盘价格低于 当期转股价格（23.97元/股）的90%，预计可能触发"宝莱转债"转股价格向下修 正条件。若触发转股价格向下修正条款 ...

汇兑损失等影响较大，而其对现金流不构成影响，2025 年 1-9 月公 司经营活动现金净流入 0.38 亿元，截至 2025 年 9 月末公司货币资金 为 6.48 亿元，当前现金储备可对短期债务有效覆盖。同时中证鹏元 也关注到，子公司苏州君康医疗科技有限公司（以下简称"苏州君康"） 的新生产线已实现投产，订单量及新增产能消化存在不确定性，仍有 不达预期效益的风险，而此类固定资产折旧亦将继续对公司利润形成 一定侵蚀，进而拖累公司业绩。 中证鹏元资信评估股份有限公司 中证鹏元公告【2026】74 号 中证鹏元关于关注广东宝莱特医用科技股份有限公司 2025 年度业绩预亏事项的公告 中证鹏元资信评估股份有限公司（以下简称"中证鹏元"）对广 东宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"， 股票代码：300246.SZ）及其发行的下述债券开展评级。除评级委托 关系外，中证鹏元及评级从业人员与公司不存在任何足以影响评级行 为独立、客观、公正的关联关系。 | 债券简称 | 上一次评级时间 | | 上一次评级结果 | | | | --- | --- | --- | --- | --- | --- | | | ...

Market Overview - The medical device sector increased by 0.9% on February 4, with SAIKOSHI leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Performers - SAIKOSHI (688338) closed at 32.11, up 10.15% with a trading volume of 63,600 shares and a transaction value of 197 million [1] - SHUOSHI BIO (6638889) closed at 71.46, up 5.69% with a trading volume of 15,900 shares and a transaction value of 113 million [1] - BAOLAIT (300246) closed at 13.51, up 2.74% with a trading volume of 166,100 shares and a transaction value of 224 million [1] Underperformers - KANGZHONG MEDICAL (688607) closed at 57.80, down 4.26% with a trading volume of 46,300 shares [2] - SINO MEDICAL (688108) closed at 22.70, down 3.77% with a trading volume of 170,600 shares and a transaction value of 387 million [2] - SANYOU MEDICAL (688085) closed at 21.05, down 3.08% with a trading volume of 39,800 shares and a transaction value of 84 million [2] Capital Flow - The medical device sector experienced a net outflow of 132 million from institutional investors, while retail investors saw a net outflow of 191 million [2] - Speculative funds had a net inflow of 323 million into the sector [2] Individual Stock Capital Flow - MAIRUI MEDICAL (300760) had a net inflow of 86.91 million from institutional investors, while retail investors had a net outflow of 169 million [3] - LIANSHENG MEDICAL (688271) saw a net inflow of 44.32 million from institutional investors, with a net outflow of 76.86 million from retail investors [3] - HUAKANG CLEAN (301235) had a net inflow of 31.25 million from institutional investors, while retail investors experienced a net outflow of 52.92 million [3]

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

证券日报网讯 1月29日，宝莱特发布公告称，公司预计2025年归属于上市公司股东的净利润为-8，000 万元至-6，000万元，上年同期为-7，144.13万元。 （文章来源：证券日报） ...

Core Viewpoint - The company is engaged in the research, production, sales, and service of medical device products, focusing on life information and support as well as nephrology medical sectors, with an expected net loss but a narrowing of losses compared to the previous year [5] Group 1: Financial Performance - The company anticipates a continued net loss during the reporting period, although the loss margin is expected to be smaller than the same period last year [5] - Revenue is projected to show slight growth, driven by enhanced management and operational efficiency [5] - The primary reason for the inability to achieve profitability is a decline in sales prices due to market competition, coupled with rising raw material costs, leading to a decrease in overall gross margin [5] Group 2: Cost Management and Impacts - The company is actively pursuing cost control and efficiency improvements, resulting in a year-on-year reduction in various expenses [5] - However, foreign exchange losses due to the depreciation of the US dollar against the Chinese yuan and high amortization costs related to convertible bonds significantly impact net profit [5] - The company has made provisions for asset impairment on inventory and certain production equipment based on prudence principles, which will affect the current net profit [5] Group 3: Future Projections - For 2025, the expected impact of non-recurring gains and losses on net profit is approximately 8.07 million yuan, primarily from government subsidies [5]

Core Viewpoint - Baolite expects a net profit attributable to shareholders of the listed company to be between -60 million and -80 million yuan for the year 2025, indicating continued losses but a narrowing of the loss compared to the previous year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to be between -95 million and -68 million yuan for 2025 [1] - Despite an increase in operating income, the company still expects to report a net loss due to various factors [1] Reasons for Losses - The primary reasons for the continued losses include: 1. Increased sales volume of most products, but a decline in sales prices due to market competition, coupled with rising raw material costs, leading to a decrease in overall gross margin [1] 2. Although the company has reduced various expenses, foreign exchange losses from the depreciation of the US dollar against the Chinese yuan and high amortization costs related to convertible bonds significantly impacted net profit [1] 3. The company has made provisions for asset impairment on inventory and certain production equipment based on the cautious principle of accounting standards due to declining product sales prices, which affected the current net profit [1] 4. Non-recurring gains and losses are expected to impact net profit by approximately 8.07 million yuan, primarily from government subsidies [1]

证券代码：300246 证券简称：宝莱特 公告编号：2026-004 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025 年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | -8,000 | ～ | -6,000 | -7,144.13 | | 股东的净利润 | 比上年同期增长 | -11.98% | ～ | 16.01% | | | 扣除非经常性损 | | -9,500 | ～ | -6,800 | -9,653.68 | | 益后的净利润 | 比上年同期增长 | 1.59% | ～ | 29.56% | | 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计，公 ...

Market Overview - The medical device sector experienced a slight decline of 0.08% on January 22, with Aisheren leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Top Performers - Baolait (300246) saw a significant increase of 11.93%, closing at 14.64 with a trading volume of 374,600 shares and a transaction value of 530 million [1] - Aojing Medical (688613) rose by 3.65%, closing at 24.12 with a trading volume of 56,300 shares and a transaction value of 134 million [1] - Adit (301580) increased by 3.64%, closing at 53.79 with a trading volume of 42,100 shares and a transaction value of 222 million [1] Underperformers - Aisheren (920050) experienced the largest decline of 12.17%, closing at 38.68 with a trading volume of 86,600 shares and a transaction value of 341 million [2] - Shuoshi Bio (688399) fell by 6.39%, closing at 79.42 with a trading volume of 46,300 shares and a transaction value of 374 million [2] - Tianchen Medical (688013) decreased by 3.78%, closing at 44.25 with a trading volume of 25,900 shares and a transaction value of 114 million [2] Capital Flow - The medical device sector saw a net outflow of 332 million from institutional investors, while retail investors contributed a net inflow of 152 million [2] - The top stocks by net inflow from retail investors included Guanhao Bio (300238) with a net inflow of 16.41 million [3] - Institutional investors showed a strong net inflow in Lianying Medical (688271) with 63.88 million, while retail investors had a net outflow of 68.63 million [3]